Targets › FCGRT
5 programs from 5 companies in 43 trials: 19 Phase 3, 18 Phase 2, 4 Phase 4, 2 Phase 1; Neurology, Other, Hematology; next expected readout Dec 2026.
Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk. (UniProt, P55899)
Open in Phaseline: the race on FCGRT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| argenx | Efgartigimod Alfa (PH20) IgG receptor FcRn large subunit p51 antagonist | FCGRT | Phase 4 | New Onset Generalized Myasthenia Gravis (gMG); Primary Sjogrens Disease; Primary Immune Thrombocytopenia; Myasthenia Gravis, Ocular … | Mar 2027 |
| UCB Biopharma SRL | Rozanolixizumab IgG receptor FcRn large subunit p51 inhibitor | FCGRT | Phase 4 | Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD); Generalized Myasthenia Gravis; Ocular Myasthenia Gravis | May 2027 |
| Johnson & Johnson (Janssen) | Nipocalimab IgG receptor FcRn large subunit p51 antagonist | FCGRT | Phase 3 | Hemolytic Disease of the Fetus and Newborn; Myasthenia Gravis; Thrombocytopenia, Neonatal Alloimmune; Sjogrens Syndrome … | Dec 2026 |
| Thomas Jefferson University | VYVGART Hytrulo IgG Fc receptor neonatal (FcRn) antagonist; reduces circulating IgG antibodies including a | FCGRT | Phase 2 | Stiff Person Syndrome | Dec 2027 |
| Sanofi | BIVV020 (SAR445088) Neonatal Fc receptor (FcRn) antagonist | FCGRT | Phase 2 | Transplant Rejection | – |
Generalized Myasthenia Gravis (5) Myasthenia Gravis (4) Thrombocytopenia, Neonatal Alloimmune (2) Ocular Myasthenia Gravis (2) Hemolytic Disease of the Fetus and Newborn (1) Sjogrens Syndrome (1) Lupus Erythematosus, Systemic (1) Myositis (1) Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) Warm Autoimmune Hemolytic Anemia (1) Healthy (1) Transplant Rejection (1)
antibody (2), mixed (1), protein or peptide (1), small molecule (1)
Johnson & Johnson (Janssen) (1) Sanofi (1) argenx (1) UCB Biopharma SRL (1) Thomas Jefferson University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.